FDA OKs Risperdal Consta for Bipolar

Xconomy Boston — 

Alkermes, the Cambridge, MA-based developer of technology to make longer-lasting drugs, said today the FDA has approved risperidone (Risperdal Consta) as a treatment for bipolar disorder. The medicine, first approved in 2003 as a long-acting drug for schizophrenia, is marketed by Johnson & Johnson using technology from Alkermes (NASDAQ: ALKS). Before today’s approval, the medicine was already Alkermes’ biggest product, and has turned it into a consistently profitable company.